BioStratum Inc. of Research Triangle Park has signed an agreement granting Genzyme Corp. of Cambridge, Mass., an option to obtain a worldwide license under BioStratum's patent rights pertaining to the diagnosis and treatment of Alport syndrome. Under a separate agreement, Genzyme will fund ongoing research under the direction of Dr. Karl Tryggvason, Ph.D., a founder of BioStratum who is studying a potential treatment of Alport syndrome using a gene perfusion technology developed in his laboratory. Tryggvason is the discoverer of the genetic basis of the basal lamina defects in Alport syndrome, a progressive and devastating kidney disease.
COPYRIGHT 2002 North Carolina Biotechnology Center
COPYRIGHT 2004 Gale Group